pISSN 1738-6756   eISSN 2092-9900
Open Access, Peer-reviewed
    J Breast Cancer. 2007 Dec;10(4):241-247. Korean.
    Published online Dec 31, 2007.
    https://doi.org/10.4048/jbc.2007.10.4.241
    Copyright © 2007 Korean Breast Cancer Society
    Original Article

    The Korean Hereditary Breast Cancer (KOHBRA) Study: Protocol Review

    Eun-Kyu Kim,1 Ku Sang Kim,2 Sue Kyung Park,3 Sei-Hyun Ahn,4 Min Hyuk Lee,5 Sung-Won Kim,1,2 and Korean Breast Cancer Society
      • 1Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
      • 2Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
      • 3Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
      • 4Department of Surgery College of Medicine, University of Ulsan and Asan Medical Center, Seoul, Korea.
      • 5Department of Surgery, College of Medicine, Soonchunhyang University, Seoul, Korea.
    Received November 01, 2007; Accepted November 30, 2007.

    Abstract

    Purpose

    Most epidemiological and clinical studies on BRCA1/2 mutations and the risk of breast cancer have been based on Western cohorts. There have been few such studies for Korean populations. The primary aim of this paper is to report the protocol of a Korean Hereditary Breast Cancer (KOHBRA) study.

    Methods

    The multi-centers registered in the Korean Breast Cancer Society are participating in the KOHBRA study. The objectives of the KOHBRA study till 2010 is to examine the prevalence of BRCA1/2 mutation and the prevalence of ovarian cancer among the high risk group of hereditary breast cancer patients and their families. This study is a prospective cohort study that recruited 2,250 subjects: 1) who were breast cancer patients with a family history of breast or ovarian cancers, 2) who were patients with a high risk of BRCA1/2 mutations (i.e. early onset, bilateral, male, multiple primary cancers), and 3) who had family members that were BRCA1/2 mutation carriers. The recruiting period will cover the 25th of May 2007 to the 24th of May 2010. Written informed consent is obtained at the time of enrollment. The family history and epidemiological data are obtained by a baseline questionnaire, the anthropometric data is measured and the clinical information is collected by chart-reviews by doctors. BRCA1/2 mutation testing and ovarian cancer screening are done. Blood samples are stored. Follow-up data are collected at 1, 3 and 5 yr after enrollment.

    Results

    Until now, 36 centers have joined the KOHBRA study and they are in the process of Institutional Review Board (IRB) approval. We expect to find the Korean founder mutation and to establish the Korean BRCA risk prediction model. Furthermore, the BRCA carrier cohort established from the KOHBRA study will be the groundwork to participate in an international study.

    Conclusion

    The KOHBRA study will provide unique, important data to prove the etiology and natural history of Korean hereditary breast cancer. This study will be continued as genomic and proteomic epidemiological studies and future intervention studies for the prevention of hereditary breast cancer among Koreans.

    Keywords
    Hereditary breast cancer; BRCA1; BRCA2; Prevalence

    Figures

    Fig 1
    Flow chart of KOHBRA study.

    Fig 2
    Study design of KOHBRA study.

    References

      1. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399–404.
      1. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–792.
      1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318–2324.
      1. Kang DH, Kim SW, Noh DY, Ahn YO, Ryu KY. Korean Breast Cancer Society. In: The Breast. 2nd ed. Ilchokak; 2005. Epidemiology of Breast Cancer; pp. 168-188.
      1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–1130.
      1. Jeong J. Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2004 using breast cancer registration program. J Breast Cancer 2006;9:151–161.
      1. Ahn SH, Yoo KY. Korean Breast Cancer Society. Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996-2004. Breast Cancer Res Treat 2006;99:209–214.
      1. Oh JH, Noh DY, Choe KJ, Kang SB, Kim LS, Ro MS, et al. Germline Mutation of BRCA1 Gene in Korean Breast and Overian Cancer Patients. J Korean Cancer Assoc 1995;27:1061–1069.
      1. Kang HC, Kim IJ, Park JH, Kwon HJ, Won YJ, Heo SC, et al. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Hum Mutat 2002;20:235.
      1. Ahn SH, Hwang UK, Kwak BS, Yoon HS, Ku BK, Kang HJ, et al. Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Korean Med Sci 2004;19:269–274.
      1. Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 2004;22:1638–1645.
      1. Han SH, Lee KR, Lee DG, Kim BY, Lee KE, Chung WS. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet 2006;70:496–501.
      1. Ahn SH, Son BH, Yoon KS, Noh DY, Han W, Kim SW, et al. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett 2007;245:90–95.
      1. Breast Cancer Information Core (BIC) database. National Human Genome Research Institute; [accessed 2007 Sept 24].
        http://research.nhgri.nih.gov/projects/bic/Member/index.shtm.
      1. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409–1415.
      1. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145–158.
      1. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480–1490.
      1. Kazerouni N, Greene MH, Lacey JV Jr, Mink PJ, Schairer C. Family history of breast cancer as a risk factor for ovarian cancer in a prospective study. Cancer 2006;107:1075–1083.
      1. Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:3776–3781.
      1. Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, et al. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 2006;15:359–363.
      1. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676–689.
      1. Kim SW, Lee CS, Fey JV, Borgen PI, Boyd J. Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases. J Med Genet 2005;42
      1. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242–1250.
      1. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663–3665.
      1. Clinical practice guidelines in oncology - v.1.2007. National Comprehensive Cancer Network; [accessed 2007 Sept 24].
        http://www.nccn.org/professionals/physician_gls/PDF.
      1. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23:1656–1663.
      1. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241–1247.
      1. International BRCA1/2 Carrier Cohort Study (IBCCS). International Agency for Research on Cancer; [accessed Sept. 24, 2007].
        http://www-gep.iarc.fr/ibccs.
      1. Lee SK, Sobal J. Socio-economic, dietary, activity, nutrition and body weight transitions in South Korea. Public Health Nutr 2003;6:665–674.
      1. Hwang JY, Shin C, Frongillo EA, Shin KR, Jo I. Secular trend in age at menarche for South Korean women born between 1920 and 1986: the Ansan Study. Ann Hum Biol 2003;30:434–442.
    Cited by
    Crossref 18
    Google Scholar 
    Web of Science 15
    MeSH Terms
    Breast Neoplasms*
    Breast*
    Cohort Studies
    Epidemiologic Studies
    Ethics Committees, Research
    Follow-Up Studies
    Humans
    Informed Consent
    Male
    Mass Screening
    Natural History
    Ovarian Neoplasms
    Prevalence
    Prospective Studies
    Surveys and Questionnaires
    Metrics
    Share
    Figures
    slide
    slide

    1 / 2

    PERMALINK